Goldman Sachs Group Analysts Give Bayer (BAYN) a €77.00 Price Target

Share on StockTwits

Bayer (FRA:BAYN) has been assigned a €77.00 ($89.53) price objective by stock analysts at Goldman Sachs Group in a note issued to investors on Wednesday, Borsen Zeitung reports. The firm currently has a “buy” rating on the healthcare company’s stock. Goldman Sachs Group’s price target indicates a potential upside of 25.12% from the company’s current price.

Several other research analysts have also recently issued reports on the stock. UBS Group set a €110.00 ($127.91) price objective on shares of Bayer and gave the company a “buy” rating in a report on Thursday, March 28th. Barclays set a €80.00 ($93.02) price objective on shares of Bayer and gave the company a “buy” rating in a report on Monday, January 21st. HSBC set a €76.00 ($88.37) price objective on shares of Bayer and gave the company a “neutral” rating in a report on Thursday, March 21st. Sanford C. Bernstein set a €86.00 ($100.00) price objective on shares of Bayer and gave the company a “buy” rating in a report on Wednesday, March 20th. Finally, JPMorgan Chase & Co. set a €70.00 ($81.40) price objective on shares of Bayer and gave the company a “neutral” rating in a report on Wednesday, January 2nd. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating and twelve have assigned a buy rating to the stock. Bayer has a consensus rating of “Hold” and a consensus price target of €81.80 ($95.12).

Shares of Bayer stock traded down €0.67 ($0.78) on Wednesday, hitting €61.54 ($71.56). The company had a trading volume of 3,835,949 shares. Bayer has a 52 week low of €91.58 ($106.49) and a 52 week high of €123.82 ($143.98).

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

See Also: Net Margin – Understanding the Different Kinds of Profit

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.